EU Clinical Trials Regulation (536/2014) and CTIS Launch: Mandatory Lay Summary Translations
Entering into application on January 31, 2022 alongside the Clinical Trials Information System (CTIS), Regulation (EU) No 536/2014 mandates that clinical trial sponsors publish plain-language Layperson Summaries in the official languages of all participating EU Member States.
Harmonizing Multi-Country Trial Submissions Through CTIS
On January 31, 2022, the European Union Clinical Trials Regulation (Regulation EU No 536/2014) officially entered into application, replacing the legacy Clinical Trials Directive (2001/20/EC). At the heart of the reform is the centralized Clinical Trials Information System (CTIS) managed by the European Medicines Agency (EMA). Under the new regime, pharmaceutical sponsors can submit a single clinical trial application across up to 30 EEA countries simultaneously, subject to strict 12-day Request for Information (RFI) response turnarounds that demand agile, pre-aligned multilingual translation workflows.
Annex V Plain-Language Summaries and Health Literacy
A landmark transparency requirement under Article 37 and Annex V of the CTR is that within 12 months of a trial’s conclusion (6 months for pediatric trials), sponsors must submit a Summary of Clinical Trial Results written in plain language understandable to laypersons. in accordance with EU Good Lay Summary Practice (GLSP), these summaries must be translated into the official national languages of every EU Member State where the trial was conducted, avoiding medical jargon while preserving scientific accuracy.
Executive Takeaways for Global Enterprises
- Key Insight: Regulation (EU) No 536/2014 and the EMA CTIS portal go live on January 31, 2022, centralizing EU clinical trial authorizations.
- Key Insight: Tight 12-day regulatory RFI windows require rapid, ISO 17100-certified medical translation workflows.
- Key Insight: Annex V mandates plain-language Layperson Summaries translated into all participating Member State languages.
¿Necesita traducciones multilingües certificadas, traducciones juradas o localización conforme a las normas ISO para sus proyectos internacionales? Solicite un presupuesto gratuito personalizado a Alphatrad y reciba una respuesta detallada en 24 horas.
Editorial & Copyright Attribution Note: This industry analysis has been independently synthesized and adapted by Alphatrad’s editorial team based on verified regulatory documentation and industry research originally published by European Medicines Agency (EMA). For the original publication and primary documentation, please consult:
Source: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-regulation
Escribe tu comentario
¿Quieres unirte a la conversación?Agradecemos tu participación.